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Abstract 
Suboptimal placental growth and development are the underlying cause of many pregnancy 
complications. No treatments are available, primarily due to the risk of causing fetal teratogenicity. 
microRNAs (miRNAs) are short, non-coding RNA sequences that regulate multiple downstream 
genes; miR-145 and miR675 have previously been identified as negative regulators of placental 
growth. In this proof of principle study, we explored the feasibility of delivering miRNA inhibitors 
to the placentas of pregnant mice and developed novel placental homing peptide-microRNA 
inhibitor conjugates for targeted enhancement of intrinsic placental growth signalling. Scrambled-, 
miR-145- or miR-675 inhibitor sequences were synthesised from peptide nucleic acids and 
conjugated to the placental homing peptide CCGKRK. Intravenous administration of the miR-145- 
and miR-675 conjugates to pregnant C57BL/6J mice significantly increased fetal and placental 
weights compared to controls; the miR-675 conjugate significantly reduced placental miR-675 
expression. When applied to human first trimester placental explants, the miR-145 conjugate 
significantly reduced placental miR-145 expression, and both conjugates induced significant 
enhancement of cytotrophoblast proliferation; no effect was observed in term placental explants. 
This study demonstrates that homing peptide-miRNA inhibitor conjugates can be exploited to 
promote placental growth; these novel therapeutics may represent an innovative strategy for 
targeted treatment of compromised placental development. 
Key words: fetal growth restriction, IGF-II, microRNA, placenta, proliferation, pregnancy. 
Introduction 
In the UK, more than 70,000 pregnant women 
per year develop serious complications such as 
pre-eclampsia, fetal growth restriction (FGR) and 
macrosomia. In the majority of cases, the underlying 
cause of these conditions is an abnormally developed 
and/or poorly functioning placenta, leading to 
iatrogenic preterm delivery. The consequences are 
twofold: in the short term, premature babies are at 
high risk of developing complications, and in later life 
affected individuals are at increased risk of 
developing cardiovascular or metabolic diseases [1,2]. 
Studies in mice have demonstrated that enhancement 
of placental function can alleviate maternal symptoms 
and promote fetal growth [3,4]. However, the 
availability of safe and effective treatments for use in 
human pregnancy is severely limited, because 
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systemic administration of drugs in human 
pregnancy may be associated with unwanted side 
effects and risk of teratogenesis [5]. Potential 
therapeutics have been identified that enhance 
placental growth and function, alleviate maternal 
symptoms and improve fetal growth in animal 
models of pregnancy complications [6], yet pregnant 
women are considered to be a high risk, low return 
cohort. As a consequence, there is a long standing 
drug drought in obstetric therapeutics: only three new 
drugs have been licensed for use in pregnancy in the 
last 20 years, two of which are used after delivery [5]. 
The human placenta consists of an outer 
syncytium, where nutrient transfer occurs, and an 
underlying layer of proliferating cytotrophoblasts 
(CTB) [7,8]. The syncytial layer has a high turnover, 
with terminally differentiated and apoptotic elements 
shedding continuously into maternal circulation. To 
support the nutritional demands of the growing fetus, 
the syncytial surface area must be maintained, so CTB 
progenitor cells divide, differentiate and fuse with the 
overlying syncytium. CTB proliferation is of the 
utmost importance for placental growth; CTB 
proliferation is maximal in the first trimester of 
pregnancy and perturbation of proliferation is 
associated with the pregnancy pathologies described 
above [9]. Abnormally high levels of proliferation can 
occur in women presenting with diabetes and are 
associated with fetal overgrowth (macrosomia) [10], 
whilst reduced levels are linked to fetal growth 
restriction and pre-eclampsia [9].  
The basal rate of CTB proliferation can be 
augmented by exogenous growth factors and 
hormones including insulin-like growth factor-I 
(IGF-I) and IGF-II, epidermal growth factor, 
transforming growth factor-β, platelet-derived 
growth factor and the fibroblast growth factor family 
[11,12]; however it is also regulated endogenously by 
the actions of specific microRNAs (miRNAs). 
miRNAs are short non-coding RNAs (18-22 
nucleotides in length) that bind to the 3’-untranslated 
region (3’UTRs) of target mRNA sequences to induce 
direct cleavage of mRNA or indirect repression of 
protein translation. To date, more than 2000 mature 
miRNAs have been identified in humans; they are 
involved in gene regulation in all cells, but the 
function and/or targets of only a small percentage of 
miRNAs is currently known. Several miRNAs that are 
key regulators of placental growth and function have 
recently been identified, including some that are 
placental-specific, such as a large cluster identified on 
chromosome 19 [13,14]. Work by our group and 
others has identified numerous miRNAs, including 
miR-675, miR-145, let-7a, miR-377 and miR-483, that 
influence events in early pregnancy [15], and can 
either positively or negatively regulate CTB 
proliferation in explants of human placental tissue 
[16-19]. Expression levels of many miRNAs are 
altered in pregnancy pathologies that are associated 
with altered placental function [20-24]. Furthermore, 
transfection of placental explants with specific 
miRNA mimetics or miRNA inhibitors can enhance or 
inhibit CTB proliferation rates [16]; thus, miRNAs 
represent valid therapeutic targets in human placental 
tissue, which can be manipulated by delivery of 
miRNA inhibitors or mimetics.  
We have previously shown that microRNA 
(miR)-145 negatively regulates IGF-I-induced 
cytotrophoblast proliferation in human placental 
explants [16], and a recent publication has identified 
miR-675 as a regulator placental growth/function in 
the mouse [25]. Whilst the mouse placenta is 
structurally somewhat different from the human 
placenta, enhanced trophoblast growth also translates 
into a larger surface area for nutrient transport [26], 
and interventions that increase murine placental 
weight are associated with an improved fetal growth 
trajectory [27,28]. We have also shown that it is 
possible to use the placental homing peptide CGKRK 
to selectively deliver a liposomally-encapsulated 
payload directly to placental tissue in vitro and in 
vivo, minimising unwanted effects in maternal organs 
and fetal tissues [27]. We therefore hypothesised that 
targeted delivery of a therapeutic that enhanced 
intrinsic placental growth signalling, rather than 
delivery of an exogenous growth signal capable of 
eliciting off target effects, would represent a novel 
treatment strategy for poor placental function. In this 
proof of principle study, we have explored the 
feasibility of using a miRNA inhibitor as putative 
therapeutic in pregnancy, designed placental homing 
peptide-microRNA inhibitor conjugates synthesised 
from peptide nucleic acids, and demonstrated that 
targeted inhibition of miR-145 and miR-675 
expression within the placenta leads to enhanced CTB 
turnover in human first trimester explants and 
increased fetal and placental weights in mice.  
Materials and Methods 
Materials 
Unless stated otherwise, all materials used were 
obtained from Sigma-Aldrich (Poole, UK). 
Homing peptide-miRNA inhibitor peptide 
nucleic acid conjugates 
Three homing peptide-miRNA inhibitor peptide 
nucleic acid (PNA) conjugates were synthesised by 
Cambridge Research Biochemicals: (i) a scrambled 
miRNA inhibitor sequence conjugated to the peptide 
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CCGKRK via a disulphide linkage (5’- ACCACGCCT 
CTCGCCAGTGTCAC-Cys-Cys-Gly-Lys-Arg-Lys-3’); 
(ii) a miR-145 inhibitor sequence conjugated to the 
peptide CCGKRK via a disulphide linkage 
(5’-CAGGTCAAAAGGGTCCTTAGGGA-Cys-Cys-Gl
y-Lys-Arg-Lys-3’); and (iii) a miR-675 inhibitor 
sequence conjugated to the peptide CCGKRK via a 
disulphide linkage (5’-ACCACGCCTCTCCCGGGTG 
TCAC-Cys-Cys-Gly-Lys-Arg-Lys-3’). A commercially 
available scrambled miRNA inhibitor and a selective 
inhibitor of miR-145, both lacking targeting peptide 
sequences were purchased from Exiqon and were 
used as negative and positive controls, respectively. 
Animal procedures  
C57/BL6J mice were housed and all procedures 
were performed in accordance with the UK Animals 
(Scientific Procedures) Act 1986 at The University of 
Manchester. Animals had free access to food and 
water and were maintained on a 12:12 h light–dark 
cycle at 21–23°C. After mating, the presence of a 
copulation plug was denoted as embryonic day 0.5 
(E0.5) of pregnancy. 
Assessment of fluorescent miRNA inhibitor 
distribution in vivo 
A 5(6)-carboxyfluorescein (FAM)-labelled, 
non-targeting miRNA inhibitor (10mg/kg; Exiqon, 
Denmark) was administered via tail vein injection to 
pregnant mice. Mice received either a single injection 
on E12.5, with tissue collection 24h later at E13.5 
(short treatment), or three separate injections on 
E12.5, E14.5 and E16.5, with tissue collection at E18.5 
(extended treatment). Following terminal cardiac 
perfusion with PBS to remove unbound inhibitor, 
tissues were collected for analysis. Organs were snap 
frozen and stored at –80 °C or fixed in neutral 
buffered formalin (4% (v/v); 24h). Sections of frozen 
tissue were fixed in ice–cold methanol (15 min), 
washed in PBS (2 X 5 min), mounted in Vectashield 
mounting medium containing DAPI (4′,6–diamidino– 
2–phenylindole; Vector Laboratories) and examined 
on a Zeiss Axiovision fluorescence microscope. 
Images were captured at the same exposure so that 
comparisons across samples could be made. 
miRNA inhibitor pilot treatment study 
Mice were intravenously injected with a 5(6)- 
carboxyfluorescein (FAM)-labelled, non-targeting 
miRNA inhibitor (10mg/kg; Exiqon, Denmark), 
receiving either a single injection on E12.5, with tissue 
collection 24h later at E13.5 (short treatment), or three 
separate injections on E12.5, E14.5 and E16.5, with 
tissue collection at E18.5 (extended treatment). The 
following parameters were measured: fetal weight, 
placental weight, litter size and number of 
resorptions. 
Homing peptide-miRNA inhibitor conjugate 
treatment study 
Mice were intravenously injected with 100 µl of 
vehicle (PBS) or 1 mg/kg of the scrambled inhibitor 
PNA conjugate, the miR-145 inhibitor PNA conjugate 
or the miR-675 inhibitor PNA conjugate on E12.5, 
E14.5 and E16.5 of pregnancy. Mice were sacrificed at 
E18.5 and the following variables measured: fetal 
weight, placental weight, litter size and number of 
resorptions. The number of animals required to 
observe a statistically significant change in fetal 
and/or placental weight following treatment (n=8 
mice/group) was determined by a power calculation 
performed using data from previous treatment 
studies. Placentas were either stored in RNALater for 
24h, then transferred to a -80°C freezer prior to RNA 
extraction, or were fixed in neutral buffered formalin 
(4% (v/v); 24h), subjected to routine histological 
processing and embedded in paraffin wax. 
Human tissue collection  
Human placentas were obtained from elective 
medical or surgical termination of pregnancy during 
the first trimester (6-12 weeks) of pregnancy. Term 
placentas from uncomplicated pregnancies (37-42 
weeks) were collected within 30 minutes of vaginal or 
elective caesarean delivery. Written informed consent 
was obtained and the study had local research ethics 
committee approval (13/NW/0205; 08/H1010/ 
55(+5)).  
Villous explant culture 
Villous tissue was randomly sampled and 
washed several times under sterile conditions, in a 1:1 
ratio of serum-free Dulbecco’s modified Eagle 
medium (DMEM) and Ham’s F12 containing 
penicillin (100IU/ml), streptomycin (100µg/ml) and 
amphotericin B (2.5µg/ml) (Lonza Biosciences, UK). 
Explants of approximately 2mm3 were dissected and 
placed into 24-well culture plates (1/well), pre-coated 
with 1% (w/v) agarose. Explants were submerged in 
1ml of DMEM/Ham’s F12 containing glutamine 
(2mM), penicillin (100IU/ml), streptomycin 
(100ug/ml) and 10% (v/v) fetal bovine serum 
(Invitrogen, UK). The tissue was maintained in 95% 
air and 5% CO2 at 37°C for up to 48h. 
 Placental explants were incubated with the 
scrambled inhibitor PNA conjugate, the miR-145 
inhibitor PNA conjugate, the miR-675 inhibitor PNA 
conjugate, the scrambled miR inhibitor or the selective 
miR-145 inhibitor (50nM) for 24 or 48h. After 24h, 
explants were submerged in RNALater for 24h, then 
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stored at -80°C prior to RNA extraction. After 48h, 
explants were washed in PBS, fixed in neutral 
buffered formalin (4% (v/v); 24h), subjected to 
routine histological processing and embedded in 
paraffin wax. 
Real-time quantitative PCR  
Total RNA was extracted from mouse and 
human placental tissue using a MirVanaTM miRNA 
Isolation Kit (Life Technologies Ltd, UK) according to 
the manufacturer’s instructions. Total RNA was 
quantified using a Quant-iT Ribogreen RNA Assay 
Kit (Invitrogen, UK) or a Nanodrop 2000 
spectrophotometer (ThermoFisher Scientific). Total 
RNA (10ng) was reverse transcribed using a 
miRCURY LNA Universal RT microRNA PCR Kit 
(Exiqon A/S; Denmark); quantification of miR-145 
and mir-675 cDNA was performed using ExiLENT 
SYBR Green master mix and primers from Exiqon in a 
Mx3000p or a Mx3005p QPCR machine (Stratagene). 
miR-145-5p target sequence: 5’ GUCCAGUUUUCC 
CAGGAAUCCCU 3’ (conserved sequence between 
mouse and human); mmu miR-675-5p target 
sequence: 5’ UGGUGCGGAAAGGGCCCACAGU 3’;  
hsa miR-675-5p target sequence: 5’ UGGUGCGGAG 
AGGGCCCACAGUG 3’. 5-carboxyl-x-rhodamine 
(ROX) was used as a passive reference dye. 
Expression was compared to a standard curve 
constructed from human reference total RNA 
(Agilent). QPCR reactions were performed in 
triplicate; miRNA expression was normalised to 
expression of the housekeeping gene 5S ribosomal 
RNA using primers from Exiqon.  
Immunohistochemistry 
Sections (5µm) of wax-embedded placenta were 
dewaxed and rehydrated using Histoclear and 
decreasing concentrations of ethanol, after which they 
were submerged in distilled water for 5 min, then 
microwaved at full power for 10 min in 0.01M sodium 
citrate buffer, pH 6.0). After cooling, the sections were 
washed in distilled water and endogenous peroxidase 
activity was quenched by incubation with 3% (v/v) 
hydrogen peroxide at room temperature for 10 min. 
Sections were washed in Tris buffered saline (TBS, 2 X 
5 min) then incubated with 5% (w/v) bovine serum 
albumin (BSA) in TBS for 30 min at room temperature. 
Primary antibodies were diluted in TBS as follows: 
mouse anti-human Ki67 (35µg/ml, Dako); rabbit 
anti-mouse Ki67 (0.84µg/ml, Dako) and applied to 
individual sections. Isotype control mouse IgG was 
diluted to the same working concentration. Slides 
were incubated overnight at 4°C in a humidity 
chamber. Slides were washed in TBS (3 X 5 min), 
biotinylated anti-mouse secondary antibodies (Dako 
UK) were diluted in TBS to 4.4µg/ml, then were 
applied to the sections and incubated for 30 minutes 
at room temperature. Slides were washed again with 
TBS as described above, followed by incubation with 
avidin peroxidase (5µg/ml) for 30 minutes at room 
temperature. Another series of washes as above 
followed and sections were incubated with the 
chromogen diaminobenzidine (DAB 0.05% (w/v); 
H2O2 0.015% (v/v)). Colour development was 
monitored under a light microscope and sections were 
then washed with dH2O, counterstained with Harris’ 
hematoxylin and washed briefly in acid/alcohol 
solution. Finally, sections were washed in warm tap 
H2O, dehydrated in increasing concentrations of 
ethanol and Histoclear and mounted with DPX.  
Tissue sections were stained in large batches to 
minimize inter-experimental variation. Slides were 
imaged using an Olympus Bx41 light microscope and 
Image ProPlus 6.0 imaging software; exposure times 
were matched at image capture. The number of 
proliferating cytotrophoblasts in human placental 
explants was counted manually using blinded 
samples. The proportion of Ki67-positive cells and the 
area of the junctional zone and labyrinth within each 
mouse placenta were quantified using HistoQuest 
image analysis software. 
Data Analysis 
Data were analysed using GraphPad Prism 
software (Version 6; GraphPad, CA). Non-parametric 
data were expressed as medians and analysed by 
Kruskal-Wallis test (unpaired data) or Friedman test 
(paired data). Levene's test was used to assess 
equality of variances. Data from a minimum of 3 
independent experiments is presented. Significance 
was taken as P<0.05. 
Results 
microRNA-145 (miR-145) expression has 
previously been documented in the human placenta 
[16]; however, no corresponding data exists in the 
mouse. Quantitative RT-PCR analysis of mouse 
placental lysates confirmed miR-145 expression 
(Figure 1A), and demonstrated that miR-145 levels 
significantly increased between E12.5 and E18.5 of 
gestation. miR-145 was also detected in the fetus 
(Figure 1B), and in the maternal heart, liver and 
uterus (Figure 1C); however, the level of expression 
did not change with gestation. As observed in human 
placental explants [16], increased miR-145 expression 
correlated with a decrease in the number of 
Ki67-positive cells throughout the placenta and 
decidua (Figure 1D, E). 
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Figure 1: miR-145 expression negatively correlates with proliferation rate in the mouse placenta. miR-145 expression was assessed in [A] mouse 
placentas, [B] fetuses and [C] maternal heart, liver and uterus at E12.5, E15.5 and E18.5 by quantitative RT-PCR and normalised to expression of 5S ribosomal RNA. 
Median, n=3 - 6; *P<0.05; Kruskal-Wallis test with Dunn’s post hoc test. [D] Immunohistochemical analysis of proliferating cells in mouse placental tissue stained with 
an antibody to Ki67 or an isotype control IgG. Diaminobenzidine (DAB) labelling, brown; nuclei counterstained with haematoxylin, blue. Scale bar represents 100µm. 
Images are representative of placentas from n=3 mice. JZ = junctional zone; Dec = decidua. [E] The percent area of Ki67-positive staining was quantified using 
Histoquest software. Median, n=3; *P<0.05, Kruskal-Wallis test with Dunn’s post hoc test.  
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Figure 2: An intravenously injected scrambled miRNA inhibitor localises to the mouse placenta. A fluorescently labelled, scrambled miRNA inhibitor 
(10 mg/kg) was intravenously administered to pregnant C57/BL6J mice via the tail vein. Mice either received a single injection on E12.5, with tissue collection 24h later 
at E13.5 (short treatment), or three separate injections on E12.5, E14.5 and E16.5, with tissue collection at E18.5 (extended treatment). Mice were subjected to 
cardiac perfusion to remove unbound inhibitor, placentas were collected, fixed and frozen; miRNA inhibitor localisation was assessed by fluorescence microscopy. 
n=3 placentas were examined from each of N=3-5 pregnant mice. Representative images are shown. Scrambled miRNA inhibitor, green; DAPI (nuclei) blue. [A] A 
section of mouse placenta stained with haematoxylin and eosin to show tissue architecture; E13.5. [B] A mouse placenta collected 24h after a tail vein injection of 
PBS (100µl); E13.5. [C] A mouse placenta collected following a short-term treatment with scrambled miRNA inhibitor; E13.5. [D] A mouse placenta collected 
following a long-term treatment with scrambled miRNA inhibitor; E18.5. Scale bar represents 100µm. 
 
Before miRNA inhibitors can be considered as a 
clinical intervention for poor placental development, 
it is important to determine whether they can be 
successfully administered to the placenta and whether 
they have any detrimental effects on maternal health 
and/or pregnancy outcome. Pregnant C57/BL6J mice 
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were exposed to a short-term treatment (single 
injection; 24h) or extended dosing (3 injections at 48h 
intervals) with a commercially available 
FAM-labelled, non-targeting miRNA inhibitor. The 
inhibitor was administered via intravenous injection 
and cardiac perfusion was undertaken prior to tissue 
harvest, to remove any inhibitor still freely circulating 
in the blood. Fluorescence microscopy revealed that 
the miRNA inhibitor was present in mouse placental 
tissue after a single 24h injection; it localised primarily 
to the junctional zone, but was also evident at lower 
and more variable levels in the labyrinth and decidua 
(Figure 2C). A similar pattern of localisation of 
reduced intensity was observed after extended 
treatment (Figure 2D), even though tissue was 
harvested two days after the final injection. No 
fluorescence was observed in the placentas of mice 
injected with a vehicle control (Figure 2B). The 
miRNA inhibitor was not observed in any fetal organs 
regardless of the treatment regimen; representative 
images of the fetal brain and abdomen are shown in 
Figure 3A. In contrast, the miRNA inhibitor was 
detected in a number of maternal tissues including the 
heart, liver, kidney and uterus (Figure 3B), indicating 
the possibility of significant off-target effects 
following systemic administration of a functional 
miRNA inhibitor.  
Both short term and extended treatment with the 
scrambled miRNA inhibitor had no significant effect 
on median fetal or placental weights (Figure S1 A-D) 
and no gross fetal abnormalities were noted. In 
addition, the scrambled inhibitor did not alter 
fetal-placental weight ratio (a measure of placental 
efficiency; Figure S1 E, F), litter size (Figure S1 G, H) 
or the number of resorptions (Figure S1 I, J). These 
data suggest that the inhibitor was well tolerated in 
pregnancy. 
We have previously demonstrated that the 
peptide sequence CCGKRK selectively accumulates in 
the placentas of pregnant mice when administered 
intravenously and is rapidly internalised into the 
outer STB later of human placental explants [27]. To 
investigate whether targeted delivery of a microRNA 
inhibitor could enhance placental growth in vivo, we 
designed CCGKRK-miRNA inhibitor conjugates 
which were synthesised using peptide nucleic acids. 
C57/BL6J mice were intravenously injected with PBS, 
a scrambled miRNA inhibitor conjugate (1mg/kg), a 
miR-145 inhibitor conjugate or a miR-675 inhibitor 
conjugate at three-time points during pregnancy. 
Mice injected with the miR-675 inhibitor conjugate 
exhibited a significant increase in median placental 
weight at E18.5, compared to mice injected with PBS 
or the scrambled inhibitor conjugate (Figure 4A). The 
miR-145 inhibitor conjugate did not significantly alter 
median placental weight, but it appeared to normalise 
placental weight, such that there were fewer of the 
heaviest and lightest placentas within that treatment 
group (Figure 4E). Levene’s test for homogeneity of 
variance confirmed that the miR-145 inhibitor 
conjugate significantly reduced the variance in 
placental weights, compared to mice treated with PBS 
(P<0.05). Analysis of placental weight distribution 
indicated that 6 placentas weighed below the 10th 
centile in PBS treated mice, and 5 placentas weighed 
below the 10th centile in mice treated with the 
scrambled inhibitor conjugate, but no placentas fell 
below the 10th weight centile in either miR-145 or 
miR-675 inhibitor conjugate-treated mice, suggestive 
of a growth-promoting effect. Placental weight 
distributions are shown in Figure 4B.  
The miR-145 and miR-675 inhibitor conjugates 
also significantly increased median fetal weight at 
E18.5, compared to mice injected with PBS (Figure 
4C); however, fetal weight distribution curves showed 
that the number of fetuses falling below the 10th 
centile remained unchanged. Whilst the scrambled 
inhibitor conjugate did not significantly alter median 
fetal weight, it did alter fetal weight distribution; the 
reason for this is currently unknown. No inhibitor 
significantly altered the median fetal/placental 
weight ratio, a measure of placental efficiency; 
however, the miR-145 inhibitor conjugates appeared 
to normalise efficiency, such that fewer placentas 
exhibited extremes of efficiency (Figure 4E). Levene’s 
test for homogeneity of variance confirmed that 
treatment with miR-145 inhibitor conjugate 
significantly reduced the variance in fetal/placental 
weight ratio, compared to that of mice treated with 
PBS (P<0.05) or the scrambled inhibitor conjugate 
(P<0.05). No PNA inhibitor conjugate significantly 
altered litter size (Figure 4F), nor the number of 
resorptions per litter (Figure 4G), demonstrating that 
this novel treatment was well tolerated in mice. 
PCR analysis of miRNA expression in placentas 
harvested at E18.5 showed that treatment with the 
miR-675 inhibitor conjugate significantly reduced 
miR-675 expression (Figure 4G), but median placental 
miR-145 expression was not significantly changed at 
this time point (Figure 4H). The extent of cell 
proliferation in the harvested mouse placentas was 
assessed by Ki67 immunostaining and quantified 
using HistoQuest image analysis software. The total 
area of positive staining was variable throughout both 
the junctional zone and the labyrinth (Figure 5A-H) 
and there was no significant difference in 
proliferation between treatment groups at E18.5 
(Figure 5I, J). Quantification of the relative areas of the 
junctional zone and labyrinth using HistoQuest 
highlighted a significant difference in median area of 
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both zones across all treatment groups; however, 
post-hoc testing did not did not reveal a significant 
difference in median area between individual 
treatments (Figure 5K, L). 
 
 
Figure 3: An intravenously injected scrambled miRNA inhibitor accumulates in maternal organs. A fluorescently labelled, scrambled miRNA inhibitor 
(10 mg/kg) was intravenously administered to pregnant C57/BL6J mice via the tail vein. Mice either received a single injection on E12.5, with tissue collection 24h later 
at E13.5 (short treatment), or three separate injections on E12.5, E14.5 and E16.5, with tissue collection at E18.5 (extended treatment). Mice were subjected to 
cardiac perfusion to remove unbound inhibitor, fetuses and maternal organs were collected, fixed and frozen; miRNA inhibitor localisation was assessed by 
fluorescence microscopy. Tissues were examined from N=3-5 pregnant mice. Representative images are shown. Scrambled miRNA inhibitor, green; DAPI (nuclei) 
blue. [A] Mouse fetuses, [B] Maternal heart, liver and uterus. Scale bar represents 100µm. 
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Figure 4:  Homing peptide-miRNA inhibitor conjugates increase fetal and placental weight in mice. Pregnant C57/BL6J mice were intravenously 
injected with PBS (100µl; N=8, n=62), a targeted scrambled miRNA inhibitor conjugate (1mg/kg; N=8, n=59), a targeted miR-145 inhibitor conjugate (N=9, n=69), or 
a targeted miR-675 inhibitor conjugate (N=9, n=56) on E12.5, E14.5 and E16.5. Mice were sacrificed at E18.5 and the following variables measured: [A] placental 
weight; [B] placental weight population distribution curve; [C] fetal weight; [D] fetal weight population distribution curve; [E] fetal/placental weight ratio; [F] 
number of fetuses per litter, [G] number of resorptions per litter. *P<0.05 , **P<0.01; Kruskal–Wallis test with Dunn’s post hoc test. Horizontal line represents 
median. Vertical dashed line in B and D represents the fifth weight centile (mg) of PBS-treated mice. [G, H] Placental expression of [H] miR-675 and [I] miR-145 
expression was assessed by quantitative RT-PCR and normalised to expression of 5S ribosomal RNA. Median, n = 2 - 3 placentas from N = 6 mice; **P<0.01, Friedman 
test with Dunn’s post hoc test. Data points in A, C, E, H and I represent individual conceptuses; data in F and G represent litter averages.  
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Figure 5:  Homing peptide-miRNA inhibitor conjugates do not increase the rate of proliferation in the mouse placenta at E18.5. [A-H] Pregnant 
C57/BL6J mice were intravenously injected with PBS (100µl), a targeted scrambled miRNA inhibitor conjugate (1mg/kg), a targeted miR-145 inhibitor conjugate or a 
targeted miR-675 inhibitor conjugate on E12.5, E14.5 and E16.5. Mice were sacrificed at E18.5. The extent of proliferation was assessed by immunostaining mouse 
placentas with an antibody to Ki67 or an isotype control IgG (inset). Diaminobenzidine (DAB) labelling is shown in brown, nuclei were counterstained with 
haematoxylin (blue). Scale bar represents 100µm. [I, J] The total area of Ki67 immunostaining was quantified using Histoquest software. Median, n=8. [K, L] The total 
area of the junctional zone and labyrinth were quantified using Histoquest software, and expressed as percentage of the total placental area (median, n=5-8). *P<0.05, 
Kruskall Wallis test. 
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 To determine whether miRNA inhibitor 
conjugates could be used to promote growth 
signalling in human placental tissue, first trimester 
and term placental explants were cultured with 
scrambled-, miR-145 inhibitor- or miR-675 inhibitor 
conjugates, or with commercially available 
scrambled- or miR-145 inhibitors that lacked the 
CCGKRK targeting sequence. After 24h of culture, 
miR-145 expression was significantly reduced in first 
trimester explants treated with the miR-145 inhibitor 
conjugate, and the reduction in expression was 
comparable to explants treated with the non-targeted 
miR-145 inhibitor (Figure 6A), as previously reported 
[16]. In contrast, there was no significant reduction in 
miR-145 expression in term placental explants 
exposed to either the targeted or non-targeted miRNA 
inhibitor conjugate (Figure 6B). miR-675 expression 
was not significantly reduced in first trimester 
explants incubated with the miR-675 inhibitor 
conjugate (Figure 6C), but this may reflect the small 
sample size and the inherent biological variability of 
human tissue samples. No effect was observed in term 
placental explants (Figure 6D). 
To investigate whether the miRNA inhibitor 
conjugates promoted human placental cell 
proliferation, first trimester (Figure 7A-F) and term 
placental explants (Figure 7G-L) were incubated with 
the conjugates for 48h and the percent of Ki67-positive 
cytotrophoblasts (CTB) was quantified. Both miRNA 
inhibitor conjugates significantly enhanced CTB 
proliferation in first trimester explants, compared to 
those treated with the scrambled inhibitor conjugate 
(Figure 7M), and this increase was comparable to that 
observed with the non-targeted miR-145 inhibitor. 
The inhibitor conjugates had no effect on 
cytotrophoblast turnover in term placental explants 
(Figure 7N). 
 
 
 
Figure 6: Homing peptide-miRNA inhibitor conjugates reduce miR-145 expression in first trimester placental explants. [A, C] First trimester and 
[B, D] term placental explants were incubated with either a targeted scrambled inhibitor conjugate, a targeted miR-145 inhibitor conjugate, a targeted miR-675 
inhibitor conjugate, a scrambled miRNA inhibitor lacking a targeting sequence or a miR-145 inhibitor lacking a targeting sequence (50nM; 24h). [A, B] miR-145 or [C, 
D] miR-675 expression was assessed by quantitative RT-PCR (median, n=4). *P<0.05, Friedman test.  
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Figure 7:  Homing peptide-miRNA inhibitor conjugates increase cytotrophoblast proliferation in first trimester placental explants. [A-F] First 
trimester and [G-L] term placental explants were incubated with either a targeted scrambled inhibitor conjugate, a targeted miR-145 inhibitor conjugate, a targeted 
miR-675 inhibitor conjugate, a scrambled miRNA inhibitor lacking a targeting sequence or a miR-145 inhibitor lacking a targeting sequence (50nM; 48h). Proliferation 
was assessed by immunohistochemical analysis of Ki67-positive cytotrophoblasts (CTB). Diaminobenzidine (DAB) labelling, brown; nuclei counterstained with 
hematoxylin (blue). Scale bar 50µm. Inset in [A] is control IgG. Percent of Ki67-positive CTB was quantified in [M] first trimester explants (median, n=6); *P<0.05 
Friedman test, and [N] term placental explants (median, n=4). 
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Discussion 
Here we describe the first report of targeted 
delivery of miRNA inhibitor to placental tissue, 
resulting in a clinically relevant enhancement of 
placental weight in healthy mice and enhanced CTB 
proliferation in human first trimester placental 
explants. We demonstrate expression of miR-145 in 
mouse placenta for the first time, propose that this 
molecule controls placental weight gain and validate 
a previous report that miR-675 is a negative regulator 
of murine placental growth [25]. The data also show 
that the PNA conjugates were successfully 
internalised into their target cells and that the 
presence of the targeting sequence did not interfere 
with miRNA inhibitor function. Indeed, the miRNA 
inhibitor PNA and targeting peptide were conjugated 
using a disulphide linkage, so that the targeting 
element would be hydrolysed and released upon 
internalisation, and not impair binding of the 
inhibitor to endogenous cellular miRNAs. The 
CCGKRK peptide was chosen due to its effective cell 
penetrating properties, as well as for its ability to 
selectively target placental tissue [27]. The conjugates 
retained their function in vivo, likely due to the 
inherent resistance of these synthetic sequences to 
digestion by proteases and nucleases [29]. They were 
also well tolerated; no pathological effects were noted 
in dams or fetuses in this study and the lack of effect 
on gross placental morphology, litter size or number 
of pregnancy losses suggests that no overt immune 
response was stimulated by the conjugates. A more 
extensive investigation will be needed to screen for 
any subtle effects that may not have been detected in 
our pilot study; however, our current data highlights 
the favourable therapeutic profile of peptide-PNA 
conjugates in pregnancy. 
A number of nanoparticle formulations have 
proven to be successful platforms for delivery of 
miRNA mimetics and antagomirs: silica nanoparticles 
conjugated to a disialoganglioside GD(2) antibody 
were used for delivery of the pro-apoptotic 
microRNA miR-34a to mice bearing neuroblastoma 
tumours [30] and peptide-decorated lipoparticles 
containing anti-miR-712 have been used to prevent 
atheroma formation in a mouse model of 
atherosclerosis [31]. Moreover, intelligent gelatinases 
stimuli nanoparticles have been used to 
co-deliver miR-200c and docetaxel to gastric cancer 
xenografts in mice, to simultaneously inhibit the 
growth of cancer stem cells and their more 
differentiated counterparts [32]. In vitro experiments 
have demonstrated that hyaluronic acid-decorated 
polymeric nanoparticles can co-deliver doxorubicin 
and miR-542-3p to breast cancer cell lines [33] and 
mesoporous silica nanoparticles have been exploited 
to simultaneously deliver a miR-122 antagomir and 
small molecule inhibitors to hepatocellular carcinoma 
cells [34]. Despite these successes, there are only 
limited reports of targeted miRNA delivery. In a 
study similar to our own, a polyarginine-PNA 
conjugate designed to inhibit miR-221 exhibited 
efficient cellular uptake and reduced miRNA 
expression in a breast cancer cells [35]. However, this 
study was confined to in vitro observations and the 
polyarginine sequence is used as a cell-penetrating 
peptide rather than a tissue-specific targeting element. 
In a more technically advanced study, targeted 
nanoparticles decorated with a cyclic RGD peptide 
were used to deliver exogenous miR-296 to tumour 
vasculature in vivo, resulting in a significant decrease 
in microvessel formulation [36]. Here, we provide the 
first report of targeted delivery of a miRNA inhibitor 
to the placenta. 
Over recent years, a plethora of miRNAs have 
been proposed as putative regulators of trophoblast 
growth and function, and manipulation of miRNA 
expression using mimetics or antagomirs has 
confirmed their functional effects. Overexpression of 
mir-378a or miR-376c significantly enhanced 
proliferation, migration and invasion of the 
extravillous trophoblast (EVT)-like cell line 
HTR8/SVneo, and both mimetics promoted 
outgrowth of primary EVT from placental explants 
[37,38]. Conversely, overexpression of miR-20a 
significantly inhibited proliferation, migration and 
invasion of the JEG-3 cell line, and inhibited the 
growth of JEG-3 tumour xenografts in nude mice [39]. 
Inhibition of miR-21 reportedly reduced proliferation, 
migration and invasion of both JEG-3 and HTR-8 cells 
[40], and transfection of primary human term 
cytotrophoblasts with mimetics or antagomirs of 
miR-210 resulted in significant changes in 
mitochondrial respiration and oxygen consumption 
[41]. Our ultimate aim is to manipulate expression of 
placental-specific miRNAs, to further reduce the risk 
of antagomirs causing off-target effects in other 
tissues, and to correct dysregulated miRNA 
expression that may underlie the pathology of 
pregnancy complications. A number of the same 
C19MC miRNAs are downregulated in gestational 
hypertension, pre-eclampsia and FGR, and 
disease-specific miRNAs have also been identified 
[20,21,42]. As many of these miRNAs, including 
miR-145, have been detected in the peripheral blood 
of women with pregnancy complications [42], the 
potential for their use as biomarkers of disease and 
signposts for development of miRNA-specific 
personalised therapies also remains to be explored. 
The downstream targets of miR-675 have already 
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been characterised in the mouse placenta and include 
the igfr1 gene [25]. We have previously demonstrated 
a reduction in miR-675 expression in the human 
placenta in the third trimester [16], but its gene targets 
and function remain to be established. Of interest is 
our observation that placental miR-675 expression 
was quite varied in mice treated with the scrambled 
inhibitor conjugate (Figure 4H); placentas were 
randomly selected for analysis and expression level 
did not correlate with placental uterine horn position, 
the pregnant dam from which the placentas came, or 
individual fetal or placental weights. The significance 
of this level of biological variability is currently 
unknown.  
We have also identified a number of 
downstream targets of miR-145 in the human 
placenta, including IGF receptor-1, cyclin D1 and p38 
MAPK [16], all of which promote growth signalling. 
In other tissues miR-145 has been identified as a 
putative tumour suppressor gene [43] and as a 
negative regulator of angiopoietin-2 [44], MUC-1 [45] 
and ADAM-17 [46]. As these molecules have been 
shown to modulate implantation [47], trophoblast 
invasion [48] and spiral artery remodelling [49] 
respectively, miR-145 inhibition in the early stages of 
gestation has the potential to regulate multiple 
aspects of human pregnancy and placental 
development. Moreover, as miR-145 limits tumour 
angiogenesis [50,51], miR-145 inhibition may promote 
the normal physiological processes of decidual 
angiogenesis and uterine spiral artery remodelling 
which are key to pregnancy success in both humans 
and mice [52,53]. These wide-ranging effects may 
highlight some of the ways in which miR-145 
inhibition may have enhanced fetal growth in our 
study, without significantly increasing placental 
weight. Indeed, analysis of the relative area of the 
labyrinth and junctional zone is indicative of a 
possible growth-promoting effect of the miR-145 
inhibitor conjugate within the junctional zone, 
although this requires further investigation.  
It is evident from our in vivo data that there was 
inherent variability in miRNA inhibition following 
administration of the conjugates and there may be a 
reason to account for this. Unlike the human uterus, 
the mouse uterus is bicornuate and perfused in series 
by a bidirectional flow of maternal blood. Thus, the 
fetuses positioned at the top and bottom of the horn 
are likely to receive the highest plasma concentration 
of conjugate, whereas those positioned in the middle 
of the horn receive blood that has already passed 
through one or more placentas and may be somewhat 
depleted of conjugate. In our study, placentas were 
randomly selected for analysis, thus our data likely 
reflects this variability in dosing. In addition, the 
conjugate may only penetrate the cell layers closest to 
the placental vasculature, so it is unlikely that miRNA 
inhibition was achieved within every single placental 
cell. Finally, placental tissue was harvested at E18.5, 
two days after the final injection. Thus, we may have 
achieved significant miRNA knockdown at earlier 
time points in gestation, but miRNA expression may 
have subsequently normalised by the time of analysis. 
Despite these challenges, we still achieved a 
significant inhibition of miR-675 with our current 
dosing regimen.  
These reasons may also explain why a significant 
increase in proliferation was not observed in the 
harvested mouse placentas despite miR-675 
inhibition. Firstly, as the rate of conjugate delivery 
may have been variable, the basal rate of proliferation 
may have also varied between individual placentas or 
different regions of the same placenta, and as 
previously described, the maximal inhibitory effect 
may have been observed earlier in gestation. Indeed, 
if this were the case, it would correlate with our data 
from human placental explants, where the miRNA 
inhibitors had maximal effect in first trimester tissue 
but had no effect in term explants. Secondly, 
enhanced proliferation would lead to an increase in 
the total number of placental cells, as well as the 
number of Ki67 positive cells; thus, the proportion of 
immunostained nuclei compared to unstained nuclei 
may have remained the same. Finally, it would not be 
surprising that some additional regulatory 
mechanisms exist to prevent excessive placental (and 
therefore fetal) overgrowth.  
We also observed that the scrambled inhibitor 
conjugate induced a non-significant increase in fetal 
weight, highlighted by the shift in fetal weight 
distribution; the authors acknowledge that this pilot 
study may not have been sufficiently powered to 
detect subtle increases in fetal weight and this 
outcome should be investigated in more detail. In 
previous studies, the off-target effects of siRNAs have 
been attributed to a number of causes, including 
regulation of unintended transcripts through partial 
sequence complementarity, induction of 
inflammatory responses via Toll-like receptor 
activation and perturbation of endogenous miRNA 
processing and function via saturation of the 
endogenous RNAi machinery [54]. Saturation of 
exportin 5 activity, a component that is shared 
between the shRNA and microRNA processing 
pathways and is required for nuclear export of both 
molecules, has also been identified as potential cause 
of off-target effects [55]. Our scrambled inhibitor 
conjugates may have acted through any of these 
mechanisms and although the outcome was enhanced 
fetal growth, this phenomenon requires further 
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investigation. However, the off-target effects of 
miRNAs can be species-specific, highlighted by a 
comparison of the off-target transcripts regulated by 
three apolipoprotein B-specific siRNAs in mouse liver 
in vivo, and in cultured mouse and human liver 
tumour cells. Numerous common off-target 
transcripts were regulated by the siRNAs in mouse 
liver cells in vitro and in vivo, but there was only 
random overlap in the off-target transcripts regulated 
by the siRNAs when the mouse and human cell lines 
were compared [56]. This was attributed to poor 
conservation of 3′ UTR sequences, and suggests that 
the off-target effects observed in our mouse study 
may not be the same as those occurring in humans.  
In summary, we have demonstrated that homing 
peptide-miRNA inhibitor conjugates can be utilised to 
enhance placental growth; hence, it should now be 
possible to manipulate the expression of placental 
miRNAs that contribute to the development of 
pre-eclampsia and FGR. This could be achieved by 
two approaches: firstly, as demonstrated in our study, 
miRNAs that are highly expressed in the first 
trimester (such as miR-145 and miR-675), and are 
negative regulators of growth and development, 
could be targeted for inhibition in women identified 
as being at high risk of impaired placentation. 
Secondly, and likely more feasible, is that miRNAs 
which are highly expressed in the second and third 
trimester, and are negative regulators of different 
aspects of placental function, could be targeted for 
inhibition in women presenting with pre-eclampsia or 
fetal growth restriction, to treat the underlying 
pathophysiology. As more research is undertaken to 
understand the wide-ranging functions of miRNAs in 
the placenta, additional therapeutic targets will 
emerge, some of which may be placental-specific 
miRNAs. We therefore believe that the design of our 
novel therapeutics can easily be adapted to facilitate 
targeted manipulation of gene expression underlying 
compromised placental development and function. 
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